Analyzing the immune repertoire for diagnostic/prognostic purposes
Immune repertoire diversity is a powerful barometer for disease status and response. Recently, clinical researchers have increasingly applied immune repertoire sequencing to monitor and predict treatment outcomes across a growing scope of cancer contexts.
“By examining the immune repertoire of cancer patients, it is possible not only to predict treatment responses and outcomes7,8,12, but also to monitor the progress of immune cell-related therapies in clinical trials. Dam-PCR is a particularly efficacious tool for analyzing immune repertoires in the context of pre- and post-treatment cancer monitoring, as it enables simultaneous analysis of all seven chains of the immune repertoire quantitatively.”
READ MORE IN CASE STUDY
Download and read this case study for an overview of how sequencing has led to the identification of clinical indicators of various disease states, uniquely applied to oncology.
